GlassScriptPhysician profile
Sean Mccalmon
NPI 1073044988
$9,698.31
in general payments reported to CMS, 2019-2025
49 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $477 · 2023: $2,714 · 2024: $3,310 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,197 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,197.23 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,600.17 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,212.72 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $735.58 | 2022-2025 | Evenity, Repatha, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.53 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $430.36 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $405.90 | 2022-2025 | |
| Antares Pharma, INC. | $383.66 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $378.69 | 2024-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $362.65 | 2022-2025 | Korlym |
| Ibsa Pharma INC. | $343.95 | 2022-2025 | Tirosint, Licart, Tirosint |
| Radius Health, INC. | $291.35 | 2022-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $269.37 | 2023-2025 | Isturisa, Signifor Lar |
| Novartis Pharmaceuticals Corporation | $228.82 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $203.44 | 2023-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $159.39 | 2023-2025 | Recorlev, Gvoke Hypopen |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $153.97 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $138.68 | 2022-2025 | Farxiga |
| Kyowa Kirin, INC. | $137.49 | 2023-2025 | Crysvita |
| Mannkind Corporation | $136.43 | 2023-2025 | Afrezza |
| Merck Sharp & Dohme LLC | $124.46 | 2024 | Keytruda |
| Averitas Pharma INC. | $116.26 | 2023-2025 | Qutenza |
| Ascendis Pharma Endocrinology INC | $101.19 | 2023-2025 | Yorvipath |
| Insulet Corporation | $93.04 | 2023-2025 | Omnipod |
| Tolmar, INC. | $87.81 | 2023-2025 | Jatenzo |
| Pfizer INC. | $83.72 | 2023-2024 | |
| Ascensia Diabetes Care US INC. | $78.95 | 2023-2025 | |
| Esperion Therapeutics, INC. | $76.09 | 2024-2025 | Nexletol |
| Neurocrine Biosciences, INC. | $68.38 | 2024-2025 | |
| Sequel Med Tech, LLC | $65.58 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $57.71 | 2023 | Adthyza |
| Ultragenyx Pharmaceutical INC. | $53.79 | 2024 | Crysvita |
| Astellas Pharma US INC | $51.93 | 2023-2025 | Veozah |
| Chiesi USA, INC. | $48.88 | 2025 | Mycapssa |
| Cequr Corporation | $45.30 | 2024-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $44.36 | 2025 | Rezdiffra |
| Soleno Therapeutics, INC. | $36.67 | 2025 | Vykat Xr |
| Halozyme INC | $33.47 | 2023 | |
| Almatica Pharma LLC | $32.81 | 2024-2025 | Teriparatide |
| Medtronic, INC. | $28.52 | 2024 | Intellis Adaptivestim |
| Beta Bionics, INC. | $27.28 | 2023 | Ilet Bionic Pancreas |
| Abbvie INC. | $25.62 | 2022-2024 | |
| Lexicon Pharmaceuticals, INC. | $19.86 | 2023 | Inpefa |
| Amarin Pharma, INC. | $19.01 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.52 | 2025 | Strensiq |
| Rhythm Pharmaceuticals, INC. | $18.11 | 2025 | Imcivree |
| Verity Pharmaceuticals INC. | $17.91 | 2025 | Tlando |
| Horizon Therapeutics Plc | $17.30 | 2023 | Tepezza |
| Dexcom, INC. | $14.86 | 2023 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $14.77 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mccalmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.